Resultados de procura - Jimmy Watson

Efficacy, Safety, and Biomarker Analysis of 5 Mg and 7.5 Mg Doses of Crizanlizumab in Patients with Sickle Cell Disease: Primary Analyses from the Phase III STAND Study por Miguel R. Abboud, Rodolfo Delfini Cançado, Mariane de Montalembert, Wally R. Smith, Hala Rimawi, Ersi Voskaridou, Birol Güvenç, Deborah Keefe, Kai Grosch, Michele L. Nassin, Jimmy Watson, Justin Yssel, Evgeniya Reshetnyak, Yvonne Adomakoh